ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects

Scynexis, Inc.6 enrolled

Overview

This is a Phase 1, open-label, single-centre, non-randomised study to evaluate the absorption, distribution, metabolism, and excretion (ADME) of an oral solution of \[14C\]-ibrexafungerp following administration in healthy male subjects. Each subject will receive a single dose of \[14C\]-ibrexafungerp and will be followed for up to 20 days. During this period total radioactivity will be measured in blood, urine and faeces. All subjects will undergo preliminary screening procedures for the study at the screening visit. Subjects will be admitted to the clinical unit on the evening prior to dosing (Day -1). A single oral dose containing \[14C\]-ibrexafungerp oral solution will be administered to subjects. Individual subjects will be released from the clinical unit following study-related procedures on Days 8 to 20 according to their % of radioactivity collected in relation to the dose administered.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Fungal Infection

Interventions

[14C]-IbrexafungerpDRUG

Radio-labeled Ibrexafungerp, single dose.

Eligibility

Sex: MALEMin age: 30 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Key Inclusion Criteria: * Healthy males * Age 30 to 65 years of age at the time of signing informed consent * Must be willing and able to participate in the whole study * Must provide written informed consent * Must agree to adhere to the contraception requirements Key Exclusion Criteria: * Subjects who have received any investigational drug in a clinical research study within the 90 days prior to Day 1 * Current smokers * Recent radiation exposure * Subjects who have been enrolled in a 14C ADME study in the last 12 months * An acute or chronic disease determined by the investigator to be clinically significant * Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis at screening as judged by the investigator * Evidence of renal impairment at screening * History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder

Locations (1)

Quotient Sciences

Nottingham, United Kingdom

Outcomes

Primary Outcomes

Mass balance

Amount recovered expressed as a percentage of the dose administered

Time frame: Day 20

Secondary Outcomes

Routes and rates of elimination of [14C]-ibrexafungerp

Metabolite concentrations in body fluids and excreta

Time frame: Day 20

Number of subjects with treatment-emergent adverse events

Time frame: Day 20

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.